BA
NEPH icon

Bard Associates’s Nephros NEPH Stock Holding History

Bard Associates’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$421K Sell
118,003
-3,199
-3% -$10.4K 0.09% 103
2026
Q1 		$361K Sell
121,202
-417
-0.3% -$1.67K 0.09% 101
2025
Q4 		$594K Sell
121,619
-5,502
-4% -$28.1K 0.15% 89
2025
Q3 		$601K Sell
127,121
-4,000
-3% -$15.7K 0.16% 110
2025
Q2 		$536K Sell
131,121
-12,100
-8% -$32.3K 0.17% 114
2025
Q1 		$246K Sell
143,221
-12,050
-8% -$18.9K 0.09% 145
2024
Q4 		$228K Sell
155,271
-17,100
-10% -$26K 0.08% 151
2024
Q3 		$295K Sell
172,371
-3,225
-2% -$6.38K 0.1% 149
2024
Q2 		$371K Sell
175,596
-3,780
-2% -$8.16K 0.14% 131
2024
Q1 		$393K Sell
179,376
-7,942
-4% -$25.2K 0.14% 130
2023
Q4 		$648K Buy
187,318
+1,279
+0.7% +$2.78K 0.25% 111
2023
Q3 		$275K Sell
186,039
-6,900
-4% -$10.3K 0.11% 144
2023
Q2 		$299K Sell
192,939
-1,350
-0.7% -$1.99K 0.12% 140
2023
Q1 		$208K Sell
194,289
-500
-0.3% -$575 0.09% 161
2022
Q4 		$225K Sell
194,789
-57,335
-23% -$61.1K 0.1% 154
2022
Q3 		$229K Sell
252,124
-11,630
-4% -$16.4K 0.1% 148
2022
Q2 		$404K Buy
263,754
+17,346
+7% +$46.8K 0.17% 121
2022
Q1 		$1.08M Buy
246,408
+13,900
+6% +$66K 0.38% 90
2021
Q4 		$1.37M Sell
232,508
-1,700
-0.7% -$12.4K 0.45% 83
2021
Q3 		$2.05M Buy
234,208
+2,700
+1% +$23.4K 0.69% 57
2021
Q2 		$2.35M Buy
231,508
+12,130
+6% +$101K 0.77% 53
2021
Q1 		$1.46M Buy
219,378
+12,530
+6% +$98.8K 0.53% 74
2020
Q4 		$1.77M Buy
206,848
+5,050
+3% +$34.1K 0.7% 50
2020
Q3 		$1.46M Sell
201,798
-671
-0.3% -$4.91K 0.77% 48
2020
Q2 		$1.7M Sell
202,469
-5,100
-2% -$40.4K 0.94% 40
2020
Q1 		$2.64M Buy
+207,569
New +$1.76M 1.94% 9

Other funds holding NEPH

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CC
Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
NA
Navellier & Associates Reno, Nevada $1.26B AUM 95.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Bard Associates's NEPH Position: Q2 2026 in Review

Bard Associates reduced its Nephros (NEPH) stake by 2.6% in Q2 2026, selling an estimated $10.4K and leaving 118,003 shares worth $421K. The position accounts for 0.09% of the portfolio, ranked #103.

Bard Associates first reported a position in NEPH in Q1 2020 and has held it in 26 quarters since. The position peaked at $2.64M in Q1 2020. 29 funds tracked by Wall St. Rank hold NEPH as of Q2 2026.

  • Bard Associates held 118,003 shares of Nephros worth $421K as of Q2 2026.
  • Bard Associates sold 3,199 Nephros shares in Q2 2026, an estimated $10.4K.
  • Nephros made up 0.09% of Bard Associates's portfolio in Q2 2026, its #103 holding.
  • Bard Associates first reported a position in Nephros in Q1 2020 and has held it in 26 quarters since.
  • Bard Associates's Nephros position peaked at $2.64M in Q1 2020.
  • 29 funds tracked by Wall St. Rank held Nephros as of Q2 2026.

Based on Bard Associates's 13F filing for Q2 2026, filed 12 Aug 2026.